ABEA

Abea Bio is a clinical-stage biotechnology company focused on developing next-generation gene editing therapies using Adenine Base Editors (ABEs). The company leverages its proprietary platform to perform precise, single-nucleotide transitions from A-T to G-C base pairs without inducing double-strand DNA breaks. This approach aims to treat a wide range of genetic disorders by correcting pathogenic mutations at their source. Abea Bio's technology is designed to improve the safety and efficiency of gene editing compared to traditional CRISPR-Cas9 methods. The company is currently advancing several pre-clinical programs targeting rare and inherited diseases.